Medroxyprogesterone Acetate
NDC Package 50102-591-40
Package Information
Medroxyprogesterone Acetate is a medication used to prevent pregnancy. Marketed by Afaxys Pharma, Llc, this product is identified by NDC 50102-591 and is authorized under FDA application ANDA210761.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50102 - Afaxys Pharma, Llc
- 50102-591 - Medroxyprogesterone Acetate
- 50102-591-40 - 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
- 50102-591 - Medroxyprogesterone Acetate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50102-591-40 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Medroxyprogesterone Acetate, labeled by Afaxys Pharma, Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Afaxys Pharma, Llc on September 21, 2020. The current certification is valid through June 30, 2023.
What are the primary indications for this medication?
This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. It works mainly by preventing the growth and release of an egg (ovulation) during your menstrual cycle. It also makes vaginal fluid thicker to help prevent sperm from reaching an egg (fertilization) and changes the lining of the uterus (womb) to prevent attachment of a fertilized egg. Medroxyprogesterone is also used to treat endometriosis. It works by lowering the amount of certain hormones in the body and decreasing the growth of abnormal tissues that cause endometriosis. This helps reduce pain and other symptoms. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).
How is this Afaxys Pharma, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50102059140. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.